Rodin Therapeutics develops therapeutics for neurological disorders by utilizing epigenetic insights to modulate gene expression. This approach targets the underlying biological mechanisms of these disorders, aiming to improve patient outcomes through more effective treatment options.
Funding
$27M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological disorders often lack effective treatments due to the complex interplay of genetic and environmental factors influencing gene expression. Current therapies may not adequately address the underlying epigenetic mechanisms contributing to disease progression.
Solution
Rodin Therapeutics is developing therapeutics that target epigenetic mechanisms to modulate gene expression for the treatment of neurological disorders. By focusing on the biological underpinnings of these conditions, Rodin aims to create more effective treatment options that can improve patient outcomes. Their approach seeks to restore healthy gene expression patterns disrupted by neurological disease.
Target Audience
The primary target audience includes individuals suffering from neurological disorders and the healthcare professionals who treat them.
Features
- Modulation of gene expression through epigenetic mechanisms
- Focus on neurological disorders
- Development of targeted therapeutics